152 related articles for article (PubMed ID: 27156516)
1. Review of Cytotoxic CA4 Analogues that Do Not Target Microtubules: Implications for CA4 Development.
Tarade D; Pandey S; McNulty J
Mini Rev Med Chem; 2017; 17(16):1507-1514. PubMed ID: 27156516
[TBL] [Abstract][Full Text] [Related]
2. Structurally simplified biphenyl combretastatin A4 derivatives retain in vitro anti-cancer activity dependent on mitotic arrest.
Tarade D; Ma D; Pignanelli C; Mansour F; Simard D; van den Berg S; Gauld J; McNulty J; Pandey S
PLoS One; 2017; 12(3):e0171806. PubMed ID: 28253265
[TBL] [Abstract][Full Text] [Related]
3. Photoswitchable anticancer activity via trans-cis isomerization of a combretastatin A-4 analog.
Sheldon JE; Dcona MM; Lyons CE; Hackett JC; Hartman MC
Org Biomol Chem; 2016 Jan; 14(1):40-9. PubMed ID: 26503632
[TBL] [Abstract][Full Text] [Related]
4. p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4.
Quan H; Xu Y; Lou L
Int J Cancer; 2008 Apr; 122(8):1730-7. PubMed ID: 18074350
[TBL] [Abstract][Full Text] [Related]
5. Vascular disrupting agent drug classes differ in effects on the cytoskeleton.
Kim S; Peshkin L; Mitchison TJ
PLoS One; 2012; 7(7):e40177. PubMed ID: 22848372
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and structure-activity relationships of constrained heterocyclic analogues of combretastatin A4.
Arthuis M; Pontikis R; Chabot GG; Seguin J; Quentin L; Bourg S; Morin-Allory L; Florent JC
ChemMedChem; 2011 Sep; 6(9):1693-705. PubMed ID: 21732536
[TBL] [Abstract][Full Text] [Related]
7. Covalent functionalization of SWCNT with combretastatin A4 for cancer therapy.
Assali M; Zaid AN; Kittana N; Hamad D; Amer J
Nanotechnology; 2018 Jun; 29(24):245101. PubMed ID: 29583132
[TBL] [Abstract][Full Text] [Related]
8. Development of novel derivatives of stilbene and macrocyclic compounds as potent of anti-microtubule factors.
Borys F; Tobiasz P; Poterała M; Krawczyk H
Biomed Pharmacother; 2021 Jan; 133():110973. PubMed ID: 33378993
[TBL] [Abstract][Full Text] [Related]
9. 1,4-Diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) enhances the cytotoxicity of combretastatin A4 independently of mitogen-activated protein kinase kinase.
Quan H; Liu H; Li C; Lou L
J Pharmacol Exp Ther; 2009 Jul; 330(1):326-33. PubMed ID: 19377096
[TBL] [Abstract][Full Text] [Related]
10. Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity.
Ducki S; Rennison D; Woo M; Kendall A; Chabert JF; McGown AT; Lawrence NJ
Bioorg Med Chem; 2009 Nov; 17(22):7698-710. PubMed ID: 19837593
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of cyclopropylamide analogues of combretastatin-A4 as novel microtubule-stabilizing agents.
Chen H; Li Y; Sheng C; Lv Z; Dong G; Wang T; Liu J; Zhang M; Li L; Zhang T; Geng D; Niu C; Li K
J Med Chem; 2013 Feb; 56(3):685-99. PubMed ID: 23356786
[TBL] [Abstract][Full Text] [Related]
12. Influence of charge transfer on the isomerisation of stilbene derivatives for application in cancer therapy.
Holzmann N; Bernasconi L; Bisby RH; Parker AW
Phys Chem Chem Phys; 2018 Nov; 20(44):27778-27790. PubMed ID: 30378611
[TBL] [Abstract][Full Text] [Related]
13. Docking, synthesis and antiproliferative activity of N-acylhydrazone derivatives designed as combretastatin A4 analogues.
do Amaral DN; Cavalcanti BC; Bezerra DP; Ferreira PM; Castro Rde P; Sabino JR; Machado CM; Chammas R; Pessoa C; Sant'Anna CM; Barreiro EJ; Lima LM
PLoS One; 2014; 9(3):e85380. PubMed ID: 24614859
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties.
Punganuru SR; Madala HR; Venugopal SN; Samala R; Mikelis C; Srivenugopal KS
Eur J Med Chem; 2016 Jan; 107():233-44. PubMed ID: 26599530
[TBL] [Abstract][Full Text] [Related]
15. Multifunctional dendrimer/combretastatin A4 inclusion complexes enable in vitro targeted cancer therapy.
Zhang M; Guo R; Wang Y; Cao X; Shen M; Shi X
Int J Nanomedicine; 2011; 6():2337-49. PubMed ID: 22072871
[TBL] [Abstract][Full Text] [Related]
16. A Chimeric Cetuximab-Functionalized Corona as a Potent Delivery System for Microtubule-Destabilizing Nanocomplexes to Hepatocellular Carcinoma Cells: A Focus on EGFR and Tubulin Intracellular Dynamics.
Poojari R; Kini S; Srivastava R; Panda D
Mol Pharm; 2015 Nov; 12(11):3908-23. PubMed ID: 26426829
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a potent microtubule-targeting agent: Synthesis and biological evaluation of water-soluble amino acid prodrug of combretastatin A-4 derivatives.
Yu K; Li R; Yang Z; Wang F; Wu W; Wang X; Nie C; Chen L
Bioorg Med Chem Lett; 2015 Jun; 25(11):2302-7. PubMed ID: 25933592
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in combretastatin A-4 codrugs for cancer therapy.
Guo K; Ma X; Li J; Zhang C; Wu L
Eur J Med Chem; 2022 Nov; 241():114660. PubMed ID: 35964428
[TBL] [Abstract][Full Text] [Related]
19. Combretastatin A4-induced differential cytotoxicity and reduced metastatic ability by inhibition of AKT function in human gastric cancer cells.
Lin HL; Chiou SH; Wu CW; Lin WB; Chen LH; Yang YP; Tsai ML; Uen YH; Liou JP; Chi CW
J Pharmacol Exp Ther; 2007 Oct; 323(1):365-73. PubMed ID: 17646428
[TBL] [Abstract][Full Text] [Related]
20. Combretastatin A4 phosphate.
West CM; Price P
Anticancer Drugs; 2004 Mar; 15(3):179-87. PubMed ID: 15014350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
